- Home
- GHY vs FULC Comparison
GHY vs FULC Comparison
Compare GHY & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GHY | FULC |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.3M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GHY | FULC |
|---|---|---|
| Price | $12.38 | $12.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 184.8K | ★ 2.6M |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $10.24 | $2.32 |
| 52 Week High | $11.92 | $15.74 |
Technical Indicators
Market Signals| Indicator | GHY | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 56.79 |
| Support Level | $12.08 | $11.98 |
| Resistance Level | $12.47 | $13.26 |
| Average True Range (ATR) | 0.09 | 1.22 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 77.95 | 51.06 |
Price Performance
Historical ComparisonAbout GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.